TY - JOUR AU - Beatty, G. L. AU - Gladney, W. L. PY - 2015 DA - 2015// TI - Immune escape mechanisms as a guide for cancer immunotherapy JO - Clin Cancer Res. NIH Public Access VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-1860 DO - 10.1158/1078-0432.CCR-14-1860 ID - Beatty2015 ER - TY - JOUR AU - Ott, P. A. AU - Hodi, F. S. AU - Robert, C. PY - 2013 DA - 2013// TI - CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0143 DO - 10.1158/1078-0432.CCR-13-0143 ID - Ott2013 ER - TY - JOUR AU - Philips, G. K. AU - Atkins, M. PY - 2015 DA - 2015// TI - Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies JO - Int Immunol VL - 27 UR - https://doi.org/10.1093/intimm/dxu095 DO - 10.1093/intimm/dxu095 ID - Philips2015 ER - TY - STD TI - FDA. FDA approves first cancer treatment for any solid tumor with a specific genetic feature. FDA. 2017. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.htm. UR - https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.htm ID - ref4 ER - TY - JOUR AU - Aguiar, P. N. AU - Santoro, I. L. AU - Tadokoro, H. AU - Lima, L. o. p. e. s. G. AU - Filardi, B. A. AU - Oliveira, P. PY - 2016 DA - 2016// TI - The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis JO - Immunotherapy. VL - 8 UR - https://doi.org/10.2217/imt-2015-0002 DO - 10.2217/imt-2015-0002 ID - Aguiar2016 ER - TY - JOUR AU - Charoentong, P. AU - Angelova, M. AU - Charoentong, P. AU - Finotello, F. AU - Angelova, M. AU - Mayer, C. PY - 2017 DA - 2017// TI - Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade resource pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkp JO - Cell Reports. VL - 18 UR - https://doi.org/10.1016/j.celrep.2016.12.019 DO - 10.1016/j.celrep.2016.12.019 ID - Charoentong2017 ER - TY - JOUR AU - Hugo, W. AU - Zaretsky, J. M. AU - Sun, L. AU - Song, C. AU - Moreno, B. H. AU - Hu-Lieskovan, S. PY - 2016 DA - 2016// TI - Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma JO - Cell VL - 165 UR - https://doi.org/10.1016/j.cell.2016.02.065 DO - 10.1016/j.cell.2016.02.065 ID - Hugo2016 ER - TY - JOUR AU - Allen, E. M. AU - Miao, D. AU - Schilling, B. AU - Shukla, S. A. AU - Blank, C. AU - Zimmer, L. PY - 2015 DA - 2015// TI - Genomic correlates of response to CTLA-4 blockade in metastatic melanoma JO - Science (80−). VL - 350 UR - https://doi.org/10.1126/science.aad0095 DO - 10.1126/science.aad0095 ID - Allen2015 ER - TY - JOUR AU - Ayers, M. AU - Lunceford, J. AU - Nebozhyn, M. AU - Murphy, E. AU - Loboda, A. AU - Kaufman, D. R. PY - 2017 DA - 2017// TI - IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade JO - J Clin Invest. VL - 127 UR - https://doi.org/10.1172/JCI91190 DO - 10.1172/JCI91190 ID - Ayers2017 ER - TY - JOUR AU - Cristescu, R. AU - Mogg, R. AU - Ayers, M. AU - Albright, A. AU - Murphy, E. AU - Yearley, J. PY - 2018 DA - 2018// TI - Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy JO - Science. VL - 362 UR - https://doi.org/10.1126/science.aar3593 DO - 10.1126/science.aar3593 ID - Cristescu2018 ER - TY - JOUR AU - Germano, G. AU - Lamba, S. AU - Rospo, G. AU - Barault, L. AU - Magrì, A. AU - Maione, F. PY - 2017 DA - 2017// TI - Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth JO - Nature. VL - 552 UR - https://doi.org/10.1038/nature24673 DO - 10.1038/nature24673 ID - Germano2017 ER - TY - JOUR AU - Jiang, P. AU - Gu, S. AU - Pan, D. AU - Fu, J. AU - Sahu, A. AU - Hu, X. PY - 2018 DA - 2018// TI - Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response JO - Nat Med. VL - 24 UR - https://doi.org/10.1038/s41591-018-0136-1 DO - 10.1038/s41591-018-0136-1 ID - Jiang2018 ER - TY - JOUR AU - Zhang, T. AU - Xie, J. AU - Arai, S. AU - Wang, L. AU - Shi, X. AU - Shi, N. PY - 2016 DA - 2016// TI - The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis JO - Oncotarget. VL - 7 ID - Zhang2016 ER - TY - JOUR AU - Seiwert, T. Y. AU - Burtness, B. AU - Mehra, R. AU - Weiss, J. AU - Berger, R. AU - Eder, J. P. PY - 2016 DA - 2016// TI - Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial JO - Lancet Oncol. VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30066-3 DO - 10.1016/S1470-2045(16)30066-3 ID - Seiwert2016 ER - TY - JOUR AU - Prat, A. AU - Navarro, A. AU - Paré, L. AU - Reguart, N. AU - Galván, P. AU - Pascual, T. PY - 2017 DA - 2017// TI - Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-3556 DO - 10.1158/0008-5472.CAN-16-3556 ID - Prat2017 ER - TY - JOUR AU - Gao, J. AU - Shi, L. Z. AU - Zhao, H. AU - Chen, J. AU - Xiong, L. AU - He, Q. PY - 2016 DA - 2016// TI - Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy JO - Cell VL - 167 ID - Gao2016 ER - TY - JOUR AU - Shields, B. D. AU - Mahmoud, F. AU - Taylor, E. M. AU - Byrum, S. D. AU - Sengupta, D. AU - Koss, B. PY - 2017 DA - 2017// TI - Indicators of responsiveness to immune checkpoint inhibitors JO - Sci Rep. VL - 7 UR - https://doi.org/10.1038/s41598-017-01000-2 DO - 10.1038/s41598-017-01000-2 ID - Shields2017 ER - TY - JOUR AU - Ascierto, M. L. AU - Makohon-Moore, A. AU - Lipson, E. J. AU - Taube, J. M. AU - McMiller, T. L. AU - Berger, A. E. PY - 2017 DA - 2017// TI - Transcriptional mechanisms of resistance to anti-PD-1 therapy JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-0270 DO - 10.1158/1078-0432.CCR-17-0270 ID - Ascierto2017 ER - TY - JOUR AU - Aguilera, T. A. AU - Giaccia, A. J. PY - 2017 DA - 2017// TI - Molecular pathways: oncologic pathways and their role in T-cell exclusion and immune evasion—a new role for the AXL receptor tyrosine kinase JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-0189 DO - 10.1158/1078-0432.CCR-17-0189 ID - Aguilera2017 ER - TY - STD TI - Trono P, Sistigu A, Palermo B, Ciliberto G, Nisticò P. Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. emergtoplifesci.org. 2017. p. 471–86. ID - ref20 ER - TY - JOUR AU - Reck, M. AU - Rodríguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csőszi, T. AU - Fülöp, A. PY - 2016 DA - 2016// TI - Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1606774 DO - 10.1056/NEJMoa1606774 ID - Reck2016 ER - TY - JOUR AU - Snyder, A. AU - Makarov, V. AU - Merghoub, T. AU - Yuan, J. AU - Zaretsky, J. M. AU - Desrichard, A. PY - 2014 DA - 2014// TI - Genetic basis for clinical response to CTLA-4 blockade in melanoma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1406498 DO - 10.1056/NEJMoa1406498 ID - Snyder2014 ER - TY - JOUR AU - Tumeh, P. C. AU - Harview, C. L. AU - Yearley, J. H. AU - Shintaku, I. P. AU - Taylor, E. J. M. AU - Robert, L. PY - 2014 DA - 2014// TI - PD-1 blockade induces responses by inhibiting adaptive immune resistance JO - Nature VL - 515 UR - https://doi.org/10.1038/nature13954 DO - 10.1038/nature13954 ID - Tumeh2014 ER - TY - JOUR AU - Baptista, M. Z. AU - Sarian, L. O. AU - Derchain, S. F. M. AU - Pinto, G. A. AU - Vassallo, J. PY - 2016 DA - 2016// TI - Prognostic significance of PD-L1 and PD-L2 in breast cancer JO - Hum Pathol VL - 47 UR - https://doi.org/10.1016/j.humpath.2015.09.006 DO - 10.1016/j.humpath.2015.09.006 ID - Baptista2016 ER - TY - STD TI - Owonikoko T, et. al. PD-L1, PD-1, and CTLA-4 as prognostic biomarkers in resected non-small cell lung cancer. http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.7551. UR - http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.7551 ID - ref25 ER -